Breast Cancer
Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancer
Published in Oncology Business Week, May 27th, 2007
The approval is based on data from the international phase III TAnDEM study which showed that the addition of Herceptin to hormonal therapy doubled the median progression-free survival (time patients live without their cancer progressing), from 2.4 months to 4.8 months.
"Today's approval means that for the first time a combination of targeted therapies is available for patients who suffer from a particularly...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Bird Flu
ADVENTRX Pharmaceuticals Reports First Quarter 2007 Financial Results - Brain Cancer
Impact of Brain Tumors Leaves Many Patients Financially Destitute - Breast Cancer
BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response - Breast Cancer
Computer-Aided Detection with Computed Radiography Effective in Detecting Breast Cancer - Breast Cancer
Five-Year Results of Cytyc's MammoSite Radiation Therapy System Presented at ASBS Annual Meeting - Breast Cancer
Fujifilm and the National Breast Cancer Foundation Provide Free Breast Cancer Screening As Part of Images of Health: Mammograms for a Million Moms Campaign - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
